ArticleDiscover oncology2026

A five-gene TAM and MYCN signature predicts prognosis and identifies MTHFD2 as a therapeutic target in neuroblastoma.

Yanhua Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.